Sunitinib cost-effective alternative to interferon-α in renal cancer

By  

Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy: A Cost-Minimization Analysis

By Ravasio Roberto   Ortega Cinzia   Sabbatini Roberto   Porta Camillo  

Clinical Drug Investigation, Vol. 31, Iss. 7, 2011-07 ,pp. : 507-517

Adis International

Access to resources Recommend Favorite

Sunitinib cost effective for renal cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 532, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma

By Chabot Isabelle   Rocchi Angela  

Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. : 837-845

Blackwell Publishing

Access to resources Recommend Favorite

First-line erlotinib maintenance cost effective in Europe

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 633, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite